John H. Krystal, M.D.
BBRF Awards & Recognition
Scientific Council Member (Joined 2003)
2019 Colvin Prizewinner for Outstanding Achievement in Mood Disorders Research
2006, 2000 Distinguished Investigator Grant
1997 Independent Investigator Grant
John H. Krystal, M.D.
Title & Institution
Robert L. McNeil, Jr. Professor of Translational Research and Professor of Psychiatry and of Neuroscience
Chair, Department of Psychiatry,
Chief of Psychiatry and Behavioral Health, Yale-New Haven Hospital
Director, Clinical Neuroscience Division, VA National Center for PTSD
Director: NIAAA Center for the Translational Neuroscience of Alcoholism
Yale University School of Medicine
BBRF Awards & Recognition
Bio
Dr. John H. Krystal is a leading expert in the areas of alcoholism, post-traumatic stress disorder, schizo-phrenia, and depression. His work links psychophar-macology, neuroimaging, molecular genetics, and computational neuroscience to study the neurobi-ology and treatment of these disorders. He is best known for leading the discovery of the rapid antide-pressant effects of ketamine in depressed patients.
In the 1990s, Dr. Krystal’s mentor and colleague, Dr. Dennis Charney, found reason to question the centrality of monoamines to depression. This led them to hypothesize that the signaling mechanisms employed by higher brain centers, particularly glutamate and GABA signaling, might be critical to depression and its treatment.
How could glutamate signaling be studied in people? This was the focus of Dr. Krystal’s laboratory. He developed the use of ketamine as a probe of the biology of depression, discovering its remarkably rapid and robust antidepressant effects in de-pressed patients. When Janssen Pharmaceuticals received FDA approval for the s-isomer of ketamine (esketamine), it was clear that they had created new hope for people with depression and had jumpstart-ed depression research.
Dr. Krystal is a member of the U.S. National Academy of Medicine. He also serves in a variety of advisory and review capacities for NIAAA, NIMH, Wellcome Trust, Brain and Behavior Research Foundation, the Broad Institute, and the Karolinska Institutet. Currently, he is co-chair of the Neuroscience Forum (NeuroForum) of the National Academies of Scienc-es, Engineering, and Medicine, a member of the NIMH National Mental Health Advisory Council, and he edits the journal, Biological Psychiatry.
Related Articles
Related Articles
Related Articles
Learn More About the Foundation
Who
We Are
The Brain & Behavior Research Foundation is a global nonprofit organization focused on improving the understanding, prevention and treatment of psychiatric and mental illnesses.
Our
Impact
Beginning in 1987, the Brain & Behavior Research Foundation was providing seed money to neuroscientists to invest in “out of the box” research that the government and other sources were unwilling to fund. Today, Brain & Behavior Research Foundation is still the leading, private philanthropy in the world in this space.
Our
People
Meet the people who make up the Brain & Behavior Research Foundation. Our staff of experts, passionate Board of Directors, and Scientific Council which includes Nobel prize winners and chairs of psychiatric departments around the world.
Annual Report
& Financials
We take our responsibility to our donors seriously and believe that our financial operations must be transparent. We're proud to say that 100% of your contribution for research is invested directly in research grants.
Media
Center
The latest news on brain and behavior research and issues that matter most to you.
